Company profile: Centrexion Therapeutics
1.1 - Company Overview
Company description
- Provider of late clinical-stage biopharmaceutical therapies for chronic pain, including CNTX-4975, a synthetic trans-capsaicin injected directly into the site of pain to treat moderate to severe knee osteoarthritis, targeting the TRPV1 receptor to selectively inactivate local pain fibers.
Products and services
- CNTX-4975: A TRPV1-targeted synthetic trans-capsaicin injection delivered directly to the pain site to selectively inactivate local pain fibers and relieve moderate-to-severe knee osteoarthritis pain.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Centrexion Therapeutics
GH Research
HQ: Ireland
Website
- Description: Provider of clinical-stage 5-MeO-DMT (mebufotenin) therapies for psychiatric and neurological disorders, initially focused on treatment-resistant depression: GH001 inhalation (Phase 2b TRD; Phase 2a bipolar II and postpartum depression), GH002 intravenous (completed Phase 1), and GH003 intranasal (preclinical).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GH Research company profile →
Magnus Medical
HQ: United States
Website
- Description: Provider of closed-loop neuromodulation technology for intractable neurological and psychiatric disorders. Offers the SAINT Neuromodulation System, a non-invasive magnetic stimulation treatment targeting brain areas associated with depression and delivered over five days, and the Open Label Optimization (OLO) clinical research program evaluating SAINT's effectiveness in Major Depressive Disorder.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Magnus Medical company profile →
VeriNOS Pharma
HQ: Germany
Website
- Description: Provider of innovative therapeutics under clinical development for cerebral diseases, focusing on traumatic brain injury. Develops drugs inhibiting a defined cascade. Product Ronopterin, a selective iNOS inhibitor, reduces brain damage and improves outcomes in traumatic brain injury, neuro-oncology, and diabetic retinopathy by decreasing glutamate and radical production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VeriNOS Pharma company profile →
Amylyx Pharmaceuticals
HQ: United States
Website
- Description: Provider of solutions for Alzheimer’s and other brain diseases, offering ALS treatments such as RELYVRIO (U.S.)/ALBRIOZA (Canada) and AMX0035, a combination of sodium phenylbutyrate and taurursodiol studied for ALS and other neurodegenerative diseases, plus a patient support program with assistance and a free drug program for eligible patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amylyx Pharmaceuticals company profile →
Cognition Therapeutics
HQ: United States
Website
- Description: Provider of neurodegenerative disease therapeutics, developing CT1812, an oral sigma-2 receptor-targeting therapy aimed at slowing progression of Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration. The company conducts clinical trials on CT1812's safety and efficacy and researches sigma-2 receptor modulators to restore neuronal responses and prevent/displace toxic protein buildup in neurons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cognition Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Centrexion Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Centrexion Therapeutics
2.2 - Growth funds investing in similar companies to Centrexion Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Centrexion Therapeutics
4.2 - Public trading comparable groups for Centrexion Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →